Development and initial application of a blade design methodology for overspeed power-regulated tidal turbines

The range and variability of flow velocities in which horizontal axis tidal stream turbines operate introduces the requirement for a power regulation method in the system. Overspeed power regulation (OSPR) has the potential to improve the structural robustness and decrease the complexity associated with active pitch power regulation methods, while removing the difficulties of operating in stalled flow. This paper presents the development of a methodology for the design of blades to be used in such systems. The method requires a site depth, maximum flow velocity and rated power or flow speed as input parameters. The pitch setting, twist and chord distribution were set as input parameters, variable through the use of alteration functions. Rotor performance has been broken down into OSPR performance metrics which consider coefficients of power and thrust, and cavitation inception. Three visual-numerical tools have been developed: the OSPR performance metrics were used in conjunction with a one-at-a-time sensitivity analysis approach to develop a design space; cavitation inception analyses gave plots of converging cavitation and pressure terms for each blade section; the local angle of attack and torque distribution across the blade designs were plotted at key turbine operation states. Alterations to pitch setting and twist distribution are shown to have most impact upon the design requirement of increased gradient in the rotor speed-efficiency relationship in the overspeed region; coupled with such alterations, targeted changes to the chord distribution have been shown to increase the maximum efficiency. The prevention of cavitation has been highlighted as a driver for speed-limiting design alterations. While facilitating blade design, the methodology also produces experiential knowledge which can be stored, and shared in graphical format

Tow-tank testing of a 1/20th scale horizontal axis tidal turbine with uncertainty analysis

Tidal turbine developers and researchers use small scale testing (i.e. tow tank and flume testing) as a cost effective and low risk way to conduct proof-of-concept studies and evaluate early stage device performance. This paper presents experimental performance data for a three-bladed 1/20th scale NREL S814 tidal turbine rotor, produced at the 4.6 × 2.5 m and 76 m long Kelvin Hydrodynamics Laboratory tow tank at Strathclyde University. The rotor performance was characterised from very low tip speed ratios to runaway for four carriage speeds. A maximum CP of 0.285 and a maximum CT of 0.452 were recorded at tip speed ratios of 3.53 and 4.45 for a carriage speed of 1 m/s. The uncertainty in the instrument calibration and experimental measurements was quantified, allowing accurate representation of the experiments in numerical models. The methodology behind the uncertainty calculations is described in this paper. The uncertainty in the experimental measurements was found to be less than 5% for over 87% of the tests. Reynolds number scaling effects were found to be influential on the rotor performance in the range of velocities tested

Supramolecular Click Chemistry for Surface Modification of Quantum Dots Mediated by Cucurbit[7]uril

Cucurbiturils (CBs), barrel-shaped macrocyclic molecules, are capable of self-assembling at the surface of nanomaterials in their native state, via their carbonyl-ringed portals. However, the symmetrical two-portal structure typically leads to aggregated nanomaterials. We demonstrate that fluorescent quantum dot (QD) aggregates linked with CBs can be broken-up, retaining CBs adsorbed at their surface, via inclusion of guests in the CB cavity. Simultaneously, the QD surface is modified by a functional tail on the guest, thus the high affinity host-guest binding (logKa > 9) enables a non-covalent, click-like modification of the nanoparticles in aqueous solution. We achieved excellent modification efficiency in several functional QD conjugates as protein labels. Inclusion of weaker-binding guests (logKa = 4-6) enables subsequent displacement with stronger binders, realising modular switchable surface chemistries. Our general "hook-and-eye" approach to host-guest chemistry at nanomaterial interfaces will lead to divergent routes for nano-architectures with rich functionalities for theranostics and photonics in aqueous systems

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

A blade design methodology for overspeed power regulation of horizontal axis tidal turbines

Employed in tidal turbines, overspeed power regulation (OSPR) can improve the structural robustness and decrease the complexity associated with active pitch methods, while removing the diffculties of operating in stalled flow. This may be a method by which the cost of tidal energy can be brought down. The aim of this research was to investigate the OSPR method, increase understanding of associated benefits and constraints, and develop a methodology for the design of suitable blades. It is identified that: the challenges to OSPR are higher rotational velocities, leading to increased voltage levels, an increased chance of cavitation on the rotor, and potentially detrimental thrust forces; these challenges may be best overcome with blade design alterations limiting the maximum rotational velocity.;The blade design methodology uses a design platform to set boundary conditions, an existing blade design as the base case, and a blade element momentum theory (BEMT) tool as the modelling method. Blade root pitch setting, twist and chord length distribution are the variable parameters investigated. A set of ospr performance metrics and a design space sensitivity analysis, with whole-blade cavitation analyses and diagnostic plots of torque and angle of attack, are used to ascertain how function-based and then precise blade design alterations affect rotor performance.;Tow tank tests defined base case rotor performance and verified the BEMT tool.Tests on the new blades allowed comparison to the base case test performance and to the BEMT prediction. Simulations showed that the new blade design regulated power without cavitation inception, without an increase in the thrust forces and with only a 3.6% drop in efficiency - as per the set boundary conditions and design requirements.The blade design methodology can be used to overcome challenges associated with overspeed and produce blades which give significant performance improvements for use in OSPR.Employed in tidal turbines, overspeed power regulation (OSPR) can improve the structural robustness and decrease the complexity associated with active pitch methods, while removing the diffculties of operating in stalled flow. This may be a method by which the cost of tidal energy can be brought down. The aim of this research was to investigate the OSPR method, increase understanding of associated benefits and constraints, and develop a methodology for the design of suitable blades. It is identified that: the challenges to OSPR are higher rotational velocities, leading to increased voltage levels, an increased chance of cavitation on the rotor, and potentially detrimental thrust forces; these challenges may be best overcome with blade design alterations limiting the maximum rotational velocity.;The blade design methodology uses a design platform to set boundary conditions, an existing blade design as the base case, and a blade element momentum theory (BEMT) tool as the modelling method. Blade root pitch setting, twist and chord length distribution are the variable parameters investigated. A set of ospr performance metrics and a design space sensitivity analysis, with whole-blade cavitation analyses and diagnostic plots of torque and angle of attack, are used to ascertain how function-based and then precise blade design alterations affect rotor performance.;Tow tank tests defined base case rotor performance and verified the BEMT tool.Tests on the new blades allowed comparison to the base case test performance and to the BEMT prediction. Simulations showed that the new blade design regulated power without cavitation inception, without an increase in the thrust forces and with only a 3.6% drop in efficiency - as per the set boundary conditions and design requirements.The blade design methodology can be used to overcome challenges associated with overspeed and produce blades which give significant performance improvements for use in OSPR

Savor the Flavor: Consumer Preferences and Variety Seeking Associated with Spicy Foods

Individuals have a basic internal need for variation in their daily lives. This study aims to expand the discussion of variety seeking consumers’ interest and willingness to incorporate spicy flavors in their daily diets. Primary data was collected through an online survey, to run MANOVA and ANOVA analysis. Results provide details of attribute-level variety seeking and their interest in different types of spicy food items specifically associated with differences in age, race, and education. These differences were associated with two spicy foods categories, snack/chip food, and fresh peppers. This project was funded by the New Mexico Chile Association